Sanofi Buys Hemophilia Drugmaker In $11.6B Deal
Sanofi has agreed to buy Bioverativ, a biopharmaceutical business focused on developing treatments for hemophilia and other rare blood disorders, for about $11.6 billion, the companies announced Monday....To view the full article, register now.
Already a subscriber? Click here to view full article